Treatment of supraventricular tachycardia acls
Treatment of supraventricular tachycardia acls Supraventricular tachycardia (SVT) is a rapid heart rhythm originating above the ventricles, characterized by sudden onset and termination. It often presents as palpitations, dizziness, or shortness of breath, and can be alarming for patients. Effective management hinges on prompt recognition and appropriate treatment, especially in emergency settings where the ACLS (Advanced Cardiovascular Life Support) protocols guide clinicians through standardized procedures.
Initial management of SVT focuses on stabilization and vagal maneuvers. Vagal maneuvers, such as the Valsalva maneuver or carotid sinus massage, aim to stimulate the vagus nerve and increase parasympathetic tone, thereby slowing conduction through the atrioventricular (AV) node. These maneuvers are non-invasive, readily accessible, and often successful as first-line interventions. Proper technique and patient monitoring are vital during these procedures to avoid adverse effects like hypotension or stroke, especially with carotid massage.
Treatment of supraventricular tachycardia acls If vagal maneuvers fail or are contraindicated—such as in patients with carotid artery disease—pharmacologic therapy becomes necessary. Adenosine is the drug of choice for acute termination of SVT. It acts rapidly by transiently blocking conduction through the AV node, which is often the critical component of reentrant circuits causing SVT. Administered as an initial rapid IV push, typically at 6 mg, followed by a flush, adenosine often results in immediate rhythm conversion. If ineffective, a second dose of 12 mg may be administered. Due to its short half-life, adenosine’s side effects are brief, but transient flushing, chest discomfort, or brief asystole can occur.
For patients who have recurrent episodes or fail pharmacologic therapy, longer-term solutions like catheter ablation are considered, which can offer a cure by disrupting abnormal conduction pathways. However, in the acute setting, pharmacologic options such as calcium channel blockers—like verapamil or diltiazem—may be used if adenosine is contraindicated or ineffective. These agents slow AV nodal conduction but should be used cautiously in patients with hypotension or heart failure. Treatment of supraventricular tachycardia acls
Treatment of supraventricular tachycardia acls In unstable patients presenting with hemodynamic compromise—hypotension, chest pain, altered mental status—cardioversion is indicated. Synchronized electrical cardioversion delivers a controlled shock synchronized with the QRS complex to restore sinus rhythm efficiently. The energy level typically starts at 50-100 Joules and can be increased if necessary. Post-cardioversion, continuous monitoring is essential, and further assessment is needed to identify underlying causes or predispositions.
Treatment of supraventricular tachycardia acls Throughout management, clinicians must remain vigilant for potential complications, including the transition to atrial fibrillation or flutter, which can increase the risk of embolic events. Ensuring adequate anticoagulation and thorough follow-up are critical components of comprehensive care.
In summary, ACLS-guided treatment of SVT involves initial vagal maneuvers, pharmacologic agents like adenosine, and cardioversion in unstable cases. Long-term management may include medications or invasive procedures, tailored to the patient’s overall health status and recurrence risk. The goal is rapid rhythm control to alleviate symptoms and reduce the risk of adverse outcomes. Treatment of supraventricular tachycardia acls
